This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites

Authoring team

Allergic rhinitis/rhinoconjunctivitis (AR/C) induced by house dust mites (HDM) often begins in childhood and negatively impacts a child’s quality of life (1):

  • HDM-induced AR/C (HDM AR/C) is usually characterised by persistent symptoms, which are most pronounced during autumn and winter periods
  • allergen immunotherapy (AIT) is the only treatment option for AR/C that targets the underlying cause of allergic disease
    • inducing immunological tolerance to the causative allergen is initiated through repeated administration of AIT; for sublingual immunotherapy (SLIT)-tablets, daily administration for 3 years is recommended to achieve a sustained disease-modifying effect
      • SQ HDM SLIT-tablet provides a standardized extract of house dust mite allergens, delivered in tablet form under the tongue (sublingually)
      • onset of clinical effects with AIT is usually observed approximately 2-3 months after initiation, as has been shown in various studies of the SQ HDM SLIT-tablet in adults/adolescents with HDM AR/C
      • efficacy and safety of SQ HDM SLIT-tablet in treating AR/C have been demonstrated in clinical studies in adults and adolescents

NICE state with respect to allergic rhinitis (2):

  • 12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT) is recommended, within its marketing authorisation, as an option for treating moderate to severe house dust mite allergic rhinitis in people 12 to 65 years that is:
    • diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test or specific immunoglobulin E [IgE]) and
    • persistent despite use of symptom-relieving medicine

The NICE committee noted that:

"..Clinical trial evidence suggests that, compared with placebo plus standard care, 12 SQ‑HDM SLIT plus standard care may reduce:

  • rhinitis symptoms and medicine use in people with house dust mite allergic rhinitis, and
  • asthma exacerbations in people with house dust mite allergic asthma.

...There is more uncertainty about the clinical effectiveness of 12 SQ-HDM SLIT for allergic asthma than for allergic rhinitis"

Reference:

  1. Schuster SA et al. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial. Lancet Reg Health Eur. 2024 Nov 26;48:101136.
  2. NICE (March 2025). 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.